Verastem stocktwits

Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019-)

Verastem was founded on the belief that most currently marketed anti-cancer drugs have little efficacy against cancer stem cells (CSCs), a progenitor subgroup of cells that some scientists believe ...Verastem Oncology (Verastem Inc) is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts , the firm is a member of NASDAQ Biotechnology Index .The forward-looking statements contained in this press release reflect Verastem Oncology's views as of the date hereof, and Verastem Oncology does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.Learn more. Track Verisign Inc. (VRSN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019-)Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates March 14, 2024 Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing ...Track Pfizer Inc (PFE) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsView the latest Verastem Inc. (VSTM) stock price, news, historical charts, analyst ratings and financial information from WSJ.

STOCKTWITS; INSIDER TRADING; SENTIMENT ANALYSIS; MANAGER PORTFOLIOS; LATE CORPORATE NEWS . Verastem, Inc. (VSTM) SEC Filing 10-K Annual Report for the fiscal year ending Sunday, December 31, 2023. Home. SEC Filings. ... Inside Verastem, Inc.'s 10-K Annual Report: Other - Other Highlight.Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival ...At Verastem Oncology, we’re on a mission to make sure no patient ever has to hear that news. We embrace the power of partnership and collaboration to develop novel cancer therapies. It’s through these collaborations that we’ll bring hope to patients with RAS pathway-driven cancers. Purposeful. Unwavering. Influential. Insightful.Get the latest Verastem Inc (VSTM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Investors. At Verastem Oncology, Inc. (NASDAQ: VSTM), we’re working to develop a portfolio of novel small-molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. We’re pushing beyond what’s known about cancer treatment and working to deliver novel treatment approaches that address ...Oct 4, 2022 · Newly Issued Patents Extend Coverage of VS-6766 and VS-6766 + Defactinib to 2038 and 2040. BOSTON -- (BUSINESS WIRE)--Oct. 4, 2022-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP ( R af A nd M ek P rogram) clinical trials.Free VSTM Stock Alerts. $11.50. -0.63 (-5.19%) (As of 05/17/2024 08:54 PM ET) Compare. Share. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media. Media Mentions Over Time. 10.

Verastem stock resides in the small cap universe with a market cap of $263M and a share price of $10.43 which is closing in on its 52-week high share price of $15.12. Over the past year, the stock ...According to our current VSTM stock forecast, the value of Verastem shares will drop by -7.22% and reach $ 3.82 per share by May 31, 2024. Per our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).VSTM stock recorded 12/30 (40%) green days with 14.86% price volatility over the last 30 days. Based on the Verastem stock forecast, it's now a ...However, these revenue estimates do illustrate how Verastem could go from pulling just over $2M to over $200M in just five years, which would be a roughly 0.4x forward price-to-sales. The industry ...Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates March 14, 2024 Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women's Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing ...

Pnc bank routing number pittsburgh.

BOSTON--(BUSINESS WIRE)--Jun. 15, 2023-- Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common stock and pre-funded warrants in an underwritten public offering.In connection with the proposed offering, Verastem Oncology intends to grant the underwriters ...Track VESTIS CORPORATION (VSTS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem, Inc. (VSTM) 4.1200 -8.0600 (-66.17%) At close: May 24 at 4:00 PM EDT. 4.2600 +0.14 (+3.40%) After hours: May 24 at 7:59 PM EDT. All. News. Press Releases. SEC Filings. Verastem (VSTM)...Insiders have sold a total of 16,432 Verastem shares in the last 24 months for a total of $168,350.95 sold. This page (NASDAQ:VSTM) was last updated on 5/25/2024 by MarketBeat.com Staff.0.49%. $84.89B. VSTM | Complete Verastem Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)

By: Brian Stuglik, CEO, Verastem Oncology. Over the past year, those of us working in pharmaceutical oncology R&D have watched with awe as industry colleagues worked together to speed vaccinations for COVID-19 from the lab to patients' arms in record time. Breakthroughs in cancer research, typically don't happen that quickly.Track Verastem Inc (VSTM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors.Verastem Oncology VSTM announced positive interim safety and efficacy data from the dose level 1 cohort of its early to mid-stage study evaluating avutometinib and …Brian Stuglik, RPh. Mr Stuglik served as the Chief Executive Officer (CEO) of Verastem Oncology from 2019 through 2023. Mr Stuglik is a global leader in the oncology pharmaceutical sector, having successfully developed, acquired, and launched several important oncology products across multiple tumor types and therapeutic approaches in his more ...Track VERSES Technologies Inc - Ordinary Shares - Class A (Sub Voting) (VRSSF) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress PDF Version Presented Positive Results from Part A of RAMP 201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) at American Society of Clinical Oncology MeetingFind the latest Stem, Inc. (STEM) stock quote, history, news and other vital information to help you with your stock trading and investing.The latest price target for Verastem ( NASDAQ: VSTM) was reported by HC Wainwright & Co. on Monday, May 13, 2024. The analyst firm set a price target for 17.50 expecting VSTM to rise to within 12 ...Stock analysis for Verastem Inc (VSTM:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Apr 30, 2024 · VSTM on Twitter. Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib ...

Verastem Inc • Biotechnology Thu 16 May, close Current 1 day ago 2 days ago 3 days ago 4 days ago 5 days ago 6 days ago 7 days ago 8 days ago 9 days ago 10 days ago 11 days ago 12 days ago 13 days ago 14 days ago 15 days ago 16 days ago 17 days ago 18 days ago 19 days ago 20 days ago 21 days ago 22 days ago 23 days ago 24 days ago 25 days ago

Verastem's (VSTM) avutometinib/Lumakras combination therapy gets the FDA's Fast Track designation to treat KRAS G12C-mutant metastatic NSCLC patients. The stock gains 8% in response.Mr Paterson joined Verastem Oncology in 2011 and was its President and Chief Operating Officer prior to becoming President and Chief Executive Officer in 2023. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief ...5.80. -0.09%. ABEO Abeona Therapeutics Inc. 4.0600. -2.64%. Find the latest Verastem, Inc. (VSTM) stock quote, history, news and other vital information to help you with your stock trading and ...Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)14 days ago. Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced business updates and reported financial results for the...Inside Verastem, Inc.'s 10-K Annual Report: Other - Other Highlight. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a product candidate or if we experience significant delays in enrollment in any clinical trials, we could be required to ...Discover real-time Verastem, Inc. Common Stock (VSTM) stock prices, quotes, historical data, news, and Insights for informed trading and investment decisions. Stay ahead with Nasdaq.Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration has granted Fast Track ...Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.Newly Issued Patents Extend Coverage of VS-6766 and VS-6766 + Defactinib to 2038 and 2040. BOSTON -- (BUSINESS WIRE)--Oct. 4, 2022-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced an update on its RAMP ( R af A nd M ek P rogram) clinical trials.

Snow white sheets wsj crossword clue.

Croton obituaries.

Fintel reports that on July 11, 2023, Truist Securities maintained coverage of Verastem (NASDAQ:VSTM) with a Buy recommendation. Analyst Price Forecast Suggests 349.13% UpsideVerastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle ...Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle ...Verastem last posted its earnings data on May 9th, 2024. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by $0.10. Verastem has generated ($4.40) earnings per share over the last year ( ($4.40) diluted earnings per share). Earnings for Verastem are expected to ...Join Us. At Verastem Oncology, every team member plays a key role in helping to develop novel cancer therapies in areas of high unmet need. If you’re looking to make a difference for patients at a company where you’ll constantly be challenged, where professional career growth is a priority, where you’ll always be heard, and where our ...The forward-looking statements contained in this press release reflect Verastem Oncology’s views as of the date hereof, and Verastem Oncology does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer. BOSTON, April 18, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of John Hayslip, M.D., an accomplished oncologist with deep clinical research, development, and commercialization experience ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Verastem, Inc. Common Stock (VSTM) Pre-Market Stock Quotes - Nasdaq offers pre ...Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition.Investors. At Verastem Oncology, Inc. (NASDAQ: VSTM), we're working to develop a portfolio of novel small-molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. We're pushing beyond what's known about cancer treatment and working to deliver novel treatment approaches that address ...Track VERSES Technologies Inc - Ordinary Shares - Class A (Sub Voting) (VRSSF) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors ….

Read more about Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung ...Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival ...Track Castor Maritime Inc (CTRM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsView Verastem, Inc VSTM investment & stock information. Get the latest Verastem, Inc VSTM detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Need a Instagram agency in Melbourne? Read reviews & compare projects by leading Instagram marketing companies. Find a company today! Development Most Popular Emerging Tech Develop...10.86. +3.43%. Discover historical prices for VSTM stock on Yahoo Finance. View daily, weekly or monthly format back to when Verastem, Inc. stock was issued.Track CytoDyn Inc (CYDY) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Inc (VSTM) Company Description. Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small ...BOSTON--(BUSINESS WIRE)--Jan. 24, 2023-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the "Preferred Stock") to affiliates of BVF Partners L.P. in a private ... Verastem stocktwits, Verastem, Inc. Common Stock (VSTM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets., Verastem, Inc. (VSTM) Company Bio. Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts., Fintel reports that on June 27, 2023, Truist Securities reiterated coverage of Verastem ( NASDAQ:VSTM) with a Buy recommendation. Analyst Price Forecast Suggests 393.85% Upside. As of June 2, 2023 ..., Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle ..., Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed ..., Track Vertiv Holdings Co - Ordinary Shares - Class A (VRT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors, Verastem Inc. Share. $4.12. After Hours: $4.37. (6.07%) +0.25. Closed: May 24, 5:57:36 PM GMT-4 · USD · NASDAQ · Disclaimer. 1D. 5D. 1M. 6M. YTD. 1Y. 5Y. MAX. search …, Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019-), The detail page will show you the real-time trend, you can click into the MSN Money website for more details, Track ARCADIUM LITHIUM PLC (ALTM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors, Investigational New Drug (IND) Submission Planned for GFH375/VS-7375 in H1 2024No FDA Approved Therapies Available Targeting KRAS G12D, the Most Prevalent KRAS Mutation in Human CancerBOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to …, Track Cassava Sciences Inc (SAVA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors, The consensus estimate for Verastem's current full-year earnings is ($4.31) per share. B. Riley also issued estimates for Verastem's FY2028 earnings at $2.37 EPS. Several other research firms ..., Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration has granted Fast Track ..., Verastem, Inc. (NasdaqCM:VSTM) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% ..., This press release includes forward-looking statements about Verastem Oncology's strategy, future plans and prospects, including statements related to the potential clinical value of various of its clinical trials, the timing of commencing and completing trials, including topline data reports, interactions with regulators and potential for ..., Piedmont Lithium Inc. analysts consensus, targets, ratings and recommendations | Australian S.E.: PLL | Australian S.E., Verastem (NASDAQ: VSTM) just reported results for the fourth quarter of 2023. Verastem reported earnings per share of -$1.10. This was below the analyst estimate for EPS of -62 cents. The company ..., Track Veritone Inc (VERI) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors, Verastem Oncology (NASDAQ:VSTM) has received FDA orphan drug designation for its drug candidate avutometinib for the treatment of a rare cancer.The orphan drug status was assigned to avutometinib ..., This means patients quickly run out of therapeutic options. At Verastem Oncology, we’re committed to ensuring options exist. For more information about the work we’re doing at Verastem Oncology, please access our Resources section or contact Julissa Viana via email at [email protected]. Press Releases. Media Kit., BOSTON--(BUSINESS WIRE)--Jan. 24, 2023-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the “Preferred Stock”) to affiliates of BVF Partners L.P. in a private ..., DVAXDynavax Technologies Corporation. 11.88. +3.66%. Find the latest Curis, Inc. (CRIS) stock quote, history, news and other vital information to help you with your stock trading and investing., Track Amazon.com Inc (AMZN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors, Track Paramount Global (PARA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors, Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!, This press release includes forward-looking statements about Verastem Oncology’s strategy, future plans and prospects, including statements related to the expected outcome and benefits of the collaboration with GenFleet, the potential clinical value of various of its clinical trials, the timing of commencing and completing trials, including ..., Verastem, Inc. (VSTM) NasdaqCM - NasdaqCM Real-time price. Currency in USD. Add to watchlist. 11.44 +0.11 (+0.97%) At close: 04:00PM EDT. 11.64 +0.20 (+1.75%) After …, Verastem Oncology, Inc. (NASDAQ: VSTM), is a biopharmaceutical company headquartered in Needham, MA. The focus of our research is developing a portfolio of novel small molecule drugs that inhibit critical RAS signaling pathways that promote cancer cell survival and tumor growth. To learn more about our research …, Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019-), Track Vanda Pharmaceuticals Inc (VNDA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors, View the latest Verastem Inc. (VSTM) stock price, news, historical charts, analyst ratings and financial information from WSJ., VSTM Stock 12 Months Forecast. $31.67. (187.91% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Verastem in the last 3 months. The average price target is $31.67 with a high forecast of $36.00 and a low forecast of $27.00. The average price target represents a 187.91% change from the last price of $11.00.